Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 01/12/17 at 10:18am

We're officially into December and only one month away from the end of the year. Among our top news this week, Bayer saw the failure of its $175 million pneumonia drug, while Pfizer managed to secure a decision by the MHRA which now makes its Viagra Connect erectile dysfunction treatment the first such drug available over-the-counter at pharmacies in the UK.

But the biggest news with our readers this week is the announcement of huge research investments by MSD and Qiagen in partnership with the UK government, bringing more than 1,000 jobs to the country.

Also, be sure to check out the new editions of our monthly newspaper Pharmafocus and our bi-annual market intelligence report Pharmafile  - both are available to read online now!

10. US federal government withdraws approval of major patient charity over donor misconduct

The federal government has rescinded authorisation for one of the US’ biggest patient assistance charities following its discovery that the organisation could have been allowing its donors to influence prescriptions and raise prices on their drugs.

9. Pharmafocus December edition and Pharmafile Autumn 2017 are both available now!

Just in time for the Christmas period, the final Pharmafocus issue of the year and the Autumn 2017 edition of Pharmafile, our bi-annual market intelligence report for the life sciences industry, are both available to read online now!

8. Sanofi admits to dangers of its dengue vaccine

After analysing six years’ worth of data on its dengue vaccine, Dengvaxia, Sanofi contacted health authorities to tell them that its vaccine posed a risk to individuals without prior exposure to the vaccine.

7. University of Virginia researchers identify new target in triple-negative breast cancer

Researchers at the University of Virginia claim they have discovered a new target for triple-negative breast cancer, a notoriously aggressive and difficult-to-treat form of the disease.

6. Bayer's $175 million pneumonia drug fails at phase 3

Bayer has been hit by the news that its latest effort in the pneumonia space, Amikacin Inhale, has failed at the Phase 3 stage.

5. Novartis’ Phase 3 migraine data could revolutionise treatment

Descriptions of treatments as ‘revolutionary’ or ‘ground-breaking’ are ten a penny in the pharmaceutical industry, very rarely do such treatments actually deliver on that promise. For Novartis, and its partner, Amgen, it may be time to get excited about its treatment for migraines, after it published strong Phase 3 data.

4. AstraZeneca continues pivot to east with Chinese collaboration

After successes in the Chinese market was noted in Q3 filings, it should be no surprise that AZ has announced further plans to cement its position in the country - by announcing a joint venture with Chinese Future Industry Investment Fund.

3. Pfizer's Viagra Connect becomes first erectile dysfunction drug available over-the-counter in UK

Pfizer's erectile dysfunction treatment Viagra Connect (sildenafil) will now be available without a prescription through UK pharmacies, thanks to a decision by the MHRA to reclassify the drug.

2. Trio, including former Novartis exec, accused of bribery to the tune of over HK$1.5 million

A trio, including a former Senior Medical Representative at Novartis, have been charged over allegedly conspiring to offer and accept bribes of more than HK$1.5 million (US$192,000) in relation to the sale of pharmaceutical products.

1. UK government unveils pharma research HQ coup

With Brexit negotiations progressing at a snail’s pace, the government needed a boost to show that its economic plans were proving fruitful and they have released news that will allow them to claim some success.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches